Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML [1]

Blood

Volumn 108, Issue 1, 2006, Pages 400-

  Meshinchi, Soheil ^a   Arceci, Robert J ^b   Sanders, Jean E ^b   Smith, Franklin O ^b   Woods, William B ^b   Radich, Jerald P ^b   Alonzo, Todd A ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOGRAFT; HUMAN; LETTER; MEDICAL LITERATURE; MEDICAL RESEARCH; PRIORITY JOURNAL;

EID: 33745626157     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-12-4938     Document Type: Letter

References (3)

1. Gale RE, Hills R, Kottaridis PD, et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood. 2005;106:3658-3665.
2. Schlenk R, Krauter J, Fröhling S, et al. Postremission therapy with an allogeneic transplantation from an HLA-matched family donor seems to overcome the negative prognostic impact of FLT3-ITD in younger patients with acute myeloid leukemia exhibiting a normal karyotype [abstract]. Blood. 2005;106:662a. Abstract 2353.
3. Arico M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med. 2000;342:998-1006.